doi: 10.2337/db21-79-LB 35 De Leon-CrutchlowD
References: Pi-Sunyer, X., Astrup, A., Fujioka, K., et al
Have any studies been carried out on weight loss patches
Here, a programmable scheduled microneedle system is introduced, delivering semaglutide instantaneously and longitudinally over a month with one skin patch administration
Phase III trials were carried out as part of the SURPASS programme to investigate its therapeutic effectiveness (glycaemic control and body weight reduction) and safety/tolerability for the treatment of patients with type 2 diabetes [90, 91]
This innovation is likely to boost adherence, increase prescription rates, and tap into new patient segments in both diabetes and obesity management